ProKidney (PROK) Gets a Sell from Bank of America Securities

Bank of America Securities analyst Jason Gerberry reiterated a Sell rating on ProKidney yesterday and set a price target of $1.00. The company’s shares opened today at $4.82.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
• Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.

Gerberry covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, Liquidia Technologies, and Exelixis. According to TipRanks, Gerberry has an average return of 1.9% and a 49.18% success rate on recommended stocks.

Currently, the analyst consensus on ProKidney is a Hold with an average price target of $4.50.

PROK market cap is currently $1.09B and has a P/E ratio of -7.20.

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PROK in relation to earlier this year. Most recently, in April 2025, Carso De-C Inmobiliaria, a Major Shareholder at PROK bought 387,393.00 shares for a total of $275,049.03.